BG107135A - Съединения, съдържащи бензоамидпиперидин и сроднисъединения - Google Patents

Съединения, съдържащи бензоамидпиперидин и сроднисъединения Download PDF

Info

Publication number: BG107135A
Authority: BG; Bulgaria
Prior art keywords: methyl; phenyl; methoxy; piperidin; ylamino
Prior art date: 2000-04-10

Application number

BG107135A

Other languages

Bulgarian (bg)

English (en)

Inventor

Eric ARNOLD

Thomas CHAPPIE

Jianhua Huang

John HUMPHREY

Arthur Nagel

Brian O'neill

Susan Sobolov-Jaynes

Lawrence VINCENT

Original Assignee

Pfizer Products Inc.

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2000-04-10

Filing date

2002-09-23

Publication date

2003-06-30

2002-09-23 Application filed by Pfizer Products Inc. filed Critical Pfizer Products Inc.

2003-06-30 Publication of BG107135A publication Critical patent/BG107135A/bg

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/14—Prodigestives, e.g. acids, enzymes, appetite stimulants, antidyspeptics, tonics, antiflatulents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/02—Nasal agents, e.g. decongestants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/10—Drugs for disorders of the urinary system of the bladder
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/04—Antipruritics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/16—Emollients or protectives, e.g. against radiation
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
- A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/08—Antiepileptics; Anticonvulsants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/20—Hypnotics; Sedatives
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
- A61P25/32—Alcohol-abuse
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
- A61P25/36—Opioid-abuse
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/10—Spiro-condensed systems
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
- C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
- C07D491/10—Spiro-condensed systems

Landscapes

Health & Medical Sciences (AREA)
Organic Chemistry (AREA)
Chemical & Material Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Engineering & Computer Science (AREA)
Bioinformatics & Cheminformatics (AREA)
Veterinary Medicine (AREA)
Public Health (AREA)
Chemical Kinetics & Catalysis (AREA)
General Chemical & Material Sciences (AREA)
Medicinal Chemistry (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Pharmacology & Pharmacy (AREA)
General Health & Medical Sciences (AREA)
Animal Behavior & Ethology (AREA)
Neurology (AREA)
Neurosurgery (AREA)
Biomedical Technology (AREA)
Psychiatry (AREA)
Addiction (AREA)
Immunology (AREA)
Pulmonology (AREA)
Pain & Pain Management (AREA)
Urology & Nephrology (AREA)
Dermatology (AREA)
Cardiology (AREA)
Orthopedic Medicine & Surgery (AREA)
Psychology (AREA)
Heart & Thoracic Surgery (AREA)
Virology (AREA)
Communicable Diseases (AREA)
Oncology (AREA)
Rheumatology (AREA)
Physical Education & Sports Medicine (AREA)
Diabetes (AREA)
Ophthalmology & Optometry (AREA)
Transplantation (AREA)
Hematology (AREA)
AIDS & HIV (AREA)
Vascular Medicine (AREA)

BG107135A 2000-04-10 2002-09-23 Съединения, съдържащи бензоамидпиперидин и сроднисъединения BG107135A (bg)

Applications Claiming Priority (3)

Application Number	Priority Date	Filing Date	Title
US19592200P	2000-04-10	2000-04-10
US21292200P	2000-06-20	2000-06-20
PCT/IB2001/000629 WO2001077100A2 (fr)	2000-04-10	2001-04-06	Composes contenant benzoamide piperidine et composes apparentes

Publications (1)

Publication Number	Publication Date
BG107135A true BG107135A (bg)	2003-06-30

Family

ID=26891472

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
BG107135A BG107135A (bg)	2000-04-10	2002-09-23	Съединения, съдържащи бензоамидпиперидин и сроднисъединения

Country Status (32)

Country	Link
EP (1)	EP1272484B1 (fr)
JP (1)	JP4001486B2 (fr)
KR (1)	KR20020087134A (fr)
CN (1)	CN1432011A (fr)
AP (1)	AP2002002647A0 (fr)
AR (2)	AR033976A1 (fr)
AT (1)	ATE299875T1 (fr)
AU (1)	AU2001246761A1 (fr)
BG (1)	BG107135A (fr)
BR (1)	BR0109936A (fr)
CA (1)	CA2405089A1 (fr)
CZ (1)	CZ20023213A3 (fr)
DE (1)	DE60112064T2 (fr)
EA (1)	EA005409B1 (fr)
EE (1)	EE200200588A (fr)
ES (1)	ES2244599T3 (fr)
HR (1)	HRP20020808A2 (fr)
HU (1)	HUP0300413A2 (fr)
IL (1)	IL152209A0 (fr)
IS (1)	IS6561A (fr)
MA (1)	MA26891A1 (fr)
MX (1)	MXPA02010029A (fr)
NO (1)	NO20024874L (fr)
NZ (1)	NZ521346A (fr)
OA (1)	OA12245A (fr)
PA (1)	PA8515101A1 (fr)
PE (1)	PE20011311A1 (fr)
PL (1)	PL358623A1 (fr)
SK (1)	SK13942002A3 (fr)
UY (1)	UY26662A1 (fr)
WO (1)	WO2001077100A2 (fr)
YU (1)	YU73902A (fr)

Families Citing this family (42)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
GB0109871D0 (en) *	2001-04-20	2001-06-13	Glaxo Group Ltd	Metering method for particulate material
WO2003053929A1 (fr) *	2001-12-21	2003-07-03	Toray Fine Chemicals Co., Ltd.	Procede de production de derives de cis-piperidine optiquement actifs
US20040006135A1 (en) *	2002-06-19	2004-01-08	Pfizer Inc.	Combination treatment for depression and anxiety
MXPA04012420A (es)	2002-06-25	2005-04-19	Wyeth Corp	Derivados de ciclotiocabamativa como moduladores de rp y uso de los mismos para tratamiento de trastornos de la piel.
TW200401637A (en)	2002-06-25	2004-02-01	Wyeth Corp	Use of thio-oxindole derivatives in treatment of skin disorders
EP1551836A1 (fr) *	2002-10-04	2005-07-13	MERCK SHARP & DOHME LTD.	Derives d'amine azabicyclique utilises en tant qu'antagonistes du recepteur nk-1
US7205328B2 (en)	2002-10-21	2007-04-17	Irm Llc	Oxindoles with anti-HIV activity
US6911544B2 (en)	2002-10-23	2005-06-28	Pfizer Inc.	Process for the preparation of (S,S)-cis-2-phenyl-3-aminopiperidine
US7022605B2 (en) *	2002-11-12	2006-04-04	Micron Technology, Inc.	Atomic layer deposition methods
MXPA05003301A (es) *	2002-11-12	2005-07-05	Pfizer Product Inc	Procedimiento para convertir una mezcla cis-trans de bencilidenaminas sustituidas en el isomero cis puro.
AU2003902882A0 (en) *	2003-06-10	2003-06-26	Fujisawa Pharmaceutical Co., Ltd.	Piperidyl derivatives
ES2246687B2 (es)	2004-02-11	2006-11-16	Miguel Muñoz Saez	Utilizacion de antagonistas no peptidicos de receptores nk1 para la produccion de apoptosis en celulas tumorales.
RU2387647C9 (ru) *	2004-08-20	2011-05-27	Таргасепт, Инк.	Применение n-арилдиазаспироциклических соединений для лечения зависимостей
TW200800959A (en)	2005-06-10	2008-01-01	Wyeth Corp	Piperazine-piperidine antagonists and agonists of the 5-HT1a receptor
WO2006135783A2 (fr) *	2005-06-10	2006-12-21	Wisconsin Alumni Research Foundation	Compositions et methodes pour moduler une angiogenese
US7507842B2 (en) *	2005-08-12	2009-03-24	Radiorx, Inc.	Cyclic nitro compounds, pharmaceutical compositions thereof and uses thereof
US20070135380A1 (en)	2005-08-12	2007-06-14	Radiorx, Inc.	O-nitro compounds, pharmaceutical compositions thereof and uses thereof
DE102006033114A1 (de)	2006-07-18	2008-01-24	Grünenthal GmbH	Spirocyclische Azaindol-Derivate
CL2008000119A1 (es)	2007-01-16	2008-05-16	Wyeth Corp	Compuestos derivados de pirazol, antagonistas del receptor nicotinico de acetilcolina; composicion farmaceutica; y uso en el tratamiento de enfermedades tales como demencia senil, alzheimer y esquizofrenia.
JP2010516734A (ja)	2007-01-24	2010-05-20	グラクソグループリミテッド	３，５−ジアミノ−６−（２，３−ジクロロフェニル）−１，２，４−トリアジンまたはｒ（−）−２，４−ジアミノ−５−（２，３−ジクロロフェニル）−６−フルオロメチルピリミジンを含む医薬組成物
US8471041B2 (en)	2010-02-09	2013-06-25	Alliant Techsystems Inc.	Methods of synthesizing and isolating N-(bromoacetyl)-3,3-dinitroazetidine and a composition including the same
SG186989A1 (en)	2010-07-14	2013-02-28	Novartis Ag	Ip receptor agonist heterocyclic compounds
ES2376564B1 (es)	2010-08-12	2013-01-24	Manuel Vicente Salinas Martín	Utilización de anticuerpos contra los receptores nk1, nk2 y/o nk3, para producir apoptosis en las células tumorales y modificar el estroma, la inmunidad y la vascularización intra y peritumorales, como tratamiento del cáncer.
US8664247B2 (en)	2011-08-26	2014-03-04	Radiorx, Inc.	Acyclic organonitro compounds for use in treating cancer
US20140308260A1 (en)	2011-10-07	2014-10-16	Radiorx, Inc.	Methods and compositions comprising a nitrite-reductase promoter for treatment of medical disorders and preservation of blood products
CA2850723C (fr)	2011-10-07	2019-07-09	Radiorx, Inc.	Composes d'organonitro thioether et utilisations medicales de ceux-ci
WO2013087964A1 (fr)	2011-12-13	2013-06-20	Servicio Andaluz De Salud	Utilisation d'agents modificateurs de l'environnement péritumoral pour le traitement du cancer
CA2891122C (fr)	2012-11-14	2021-07-20	The Johns Hopkins University	Methodes et compositions pour le traitement de la schizophrenie
RU2506077C1 (ru) *	2013-01-25	2014-02-10	Общество С Ограниченной Ответственностью "Валента-Интеллект"	Комбинация для профилактики, коррекции и терапии боли, связанной с нейродегенерацией или ассоциированной с соматоформными расстройствами
ES2493693B1 (es)	2013-02-11	2015-07-07	Servicio Andaluz De Salud	Método para predecir o pronosticar la respuesta de un sujeto humano que padece un cáncer al tratamiento con un antagonista del receptor NK1
JP2016507582A (ja)	2013-02-13	2016-03-10	ノバルティスアーゲー	Ｉｐ受容体アゴニスト複素環式化合物
ES2541870B1 (es)	2013-12-27	2016-05-12	Servicio Andaluz De Salud	Uso de antagonistas no peptídicos de NK1 en una determinada dosis para el tratamiento del cáncer
WO2016105448A1 (fr) *	2014-12-22	2016-06-30	Darryl Rideout	Ligands du récepteur aux imidazolines de type 1 à utiliser en tant qu'agents thérapeutiques
US10342778B1 (en)	2015-10-20	2019-07-09	Epicentrx, Inc.	Treatment of brain metastases using organonitro compound combination therapy
US9987270B1 (en)	2015-10-29	2018-06-05	Epicentrix, Inc.	Treatment of gliomas using organonitro compound combination therapy
WO2017123593A1 (fr)	2016-01-11	2017-07-20	Epicentrx, Inc.	Compositions et méthodes d'administration par intraveineuse de 2-bromo-1-(3,3-dinitroazétidine-1-yl)éthanone
RU2643091C2 (ru) *	2016-04-08	2018-01-31	Федеральное государственное бюджетное научное учреждение "Научно-исследовательский институт фармакологии имени В.В. Закусова"	Производные оксимов 4-бензоилпиридина, обладающие противосудорожной активностью, как средства лечения эпилепсии и пароксизмальных состояний
CN110352190A (zh)	2016-10-14	2019-10-18	埃皮辛特瑞柯斯公司	用于医疗用途的磺氧基烷基有机硝基和相关化合物和药物组合物
WO2019010447A1 (fr)	2017-07-07	2019-01-10	Epicentrx, Inc.	Compositions pour une administration parentérale d'agents thérapeutiques
US11510901B2 (en)	2018-01-08	2022-11-29	Epicentrx, Inc.	Methods and compositions utilizing RRx-001 combination therapy for radioprotection
US20230257348A1 (en) *	2020-08-18	2023-08-17	Merck Sharp & Dohme Llc	Cyclopentapyrrole orexin receptor agonists
AU2023235233A1 (en)	2022-03-14	2024-09-12	Slap Pharmaceuticals Llc	Multicyclic compounds

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US3539584A (en) *	1967-11-14	1970-11-10	Colgate Palmolive Co	5-substituted-2,1-benzisothiazolines
US4581356A (en) *	1983-03-22	1986-04-08	Fujisawa Pharmaceutical Co., Ltd.	Triazine derivatives, and pharmaceutical compositions comprising the same
ATE121389T1 (de) *	1990-09-28	1995-05-15	Pfizer	Ringverknüpfte analoge von stickstoffenthaltenden nichtaromatischen heterocyclen.
TW202432B (fr) *	1991-06-21	1993-03-21	Pfizer
WO1997003066A1 (fr) *	1995-07-07	1997-01-30	Pfizer Pharmaceuticals Inc.	Composes de benzolactam substitues utilises comme antagonistes de la substance p
TWI220143B (en) *	1998-05-13	2004-08-11	Solvay Pharm Gmbh	Method for stereochemically controlled production of isomerically pure highly substituted azacyclic compounds and novel cyclic compounds, and intermediate products
WO2000073312A1 (fr) *	1999-05-26	2000-12-07	Astrazeneca Ab	Composes
SE9901901D0 (sv) *	1999-05-26	1999-05-26	Astra Ab	Compounds

2001
- 2001-04-06 AU AU2001246761A patent/AU2001246761A1/en not_active Abandoned
- 2001-04-06 EA EA200200963A patent/EA005409B1/ru not_active IP Right Cessation
- 2001-04-06 IL IL15220901A patent/IL152209A0/xx unknown
- 2001-04-06 BR BR0109936-1A patent/BR0109936A/pt not_active IP Right Cessation
- 2001-04-06 NZ NZ521346A patent/NZ521346A/en unknown
- 2001-04-06 CA CA002405089A patent/CA2405089A1/fr not_active Abandoned
- 2001-04-06 AP APAP/P/2002/002647A patent/AP2002002647A0/en unknown
- 2001-04-06 MX MXPA02010029A patent/MXPA02010029A/es active IP Right Grant
- 2001-04-06 SK SK1394-2002A patent/SK13942002A3/sk not_active Application Discontinuation
- 2001-04-06 EP EP01919702A patent/EP1272484B1/fr not_active Expired - Lifetime
- 2001-04-06 PL PL01358623A patent/PL358623A1/xx not_active Application Discontinuation
- 2001-04-06 WO PCT/IB2001/000629 patent/WO2001077100A2/fr active IP Right Grant
- 2001-04-06 JP JP2001575573A patent/JP4001486B2/ja not_active Expired - Fee Related
- 2001-04-06 CZ CZ20023213A patent/CZ20023213A3/cs unknown
- 2001-04-06 CN CN01807882A patent/CN1432011A/zh active Pending
- 2001-04-06 EE EEP200200588A patent/EE200200588A/xx unknown
- 2001-04-06 OA OA1200200312A patent/OA12245A/en unknown
- 2001-04-06 AT AT01919702T patent/ATE299875T1/de not_active IP Right Cessation
- 2001-04-06 KR KR1020027013582A patent/KR20020087134A/ko not_active Application Discontinuation
- 2001-04-06 HU HU0300413A patent/HUP0300413A2/hu unknown
- 2001-04-06 YU YU73902A patent/YU73902A/sh unknown
- 2001-04-06 DE DE60112064T patent/DE60112064T2/de not_active Expired - Fee Related
- 2001-04-06 ES ES01919702T patent/ES2244599T3/es not_active Expired - Lifetime
- 2001-04-09 AR ARP010101678A patent/AR033976A1/es unknown
- 2001-04-10 UY UY26662A patent/UY26662A1/es not_active Application Discontinuation
- 2001-04-10 PE PE2001000329A patent/PE20011311A1/es not_active Application Discontinuation
- 2001-04-10 PA PA20018515101A patent/PA8515101A1/es unknown
2002
- 2002-09-20 IS IS6561A patent/IS6561A/is unknown
- 2002-09-23 BG BG107135A patent/BG107135A/bg unknown
- 2002-10-02 MA MA26848A patent/MA26891A1/fr unknown
- 2002-10-09 NO NO20024874A patent/NO20024874L/no not_active Application Discontinuation
- 2002-10-10 HR HRP20020808 patent/HRP20020808A2/hr not_active Application Discontinuation
2003
- 2003-06-26 AR ARP030102296A patent/AR040346A2/es unknown

Also Published As

Publication number	Publication date
KR20020087134A (ko)	2002-11-21
ES2244599T3 (es)	2005-12-16
AR033976A1 (es)	2004-01-21
PL358623A1 (en)	2004-08-09
HRP20020808A2 (en)	2004-12-31
WO2001077100A3 (fr)	2002-03-07
JP4001486B2 (ja)	2007-10-31
PA8515101A1 (es)	2002-08-26
EE200200588A (et)	2004-04-15
EA200200963A1 (ru)	2003-02-27
MA26891A1 (fr)	2004-12-20
ATE299875T1 (de)	2005-08-15
BR0109936A (pt)	2003-05-06
CZ20023213A3 (cs)	2003-12-17
IL152209A0 (en)	2003-05-29
NO20024874D0 (no)	2002-10-09
NZ521346A (en)	2004-07-30
NO20024874L (no)	2002-11-18
SK13942002A3 (sk)	2004-03-02
AR040346A2 (es)	2005-03-30
JP2004501072A (ja)	2004-01-15
OA12245A (en)	2003-11-10
HUP0300413A2 (hu)	2003-06-28
CN1432011A (zh)	2003-07-23
YU73902A (sh)	2005-09-19
UY26662A1 (es)	2001-11-30
PE20011311A1 (es)	2001-12-25
CA2405089A1 (fr)	2001-10-18
EP1272484B1 (fr)	2005-07-20
DE60112064T2 (de)	2006-06-01
WO2001077100A2 (fr)	2001-10-18
EA005409B1 (ru)	2005-02-24
AP2002002647A0 (en)	2002-12-31
IS6561A (is)	2002-09-20
DE60112064D1 (de)	2005-08-25
AU2001246761A1 (en)	2001-10-23
EP1272484A2 (fr)	2003-01-08
MXPA02010029A (es)	2003-02-12

Publication	Publication Date	Title
BG107135A (bg)	2003-06-30	Съединения, съдържащи бензоамидпиперидин и сроднисъединения
JP3042894B2 (ja)	2000-05-22	サブスタンスｐアンタゴニストとしての置換ベンゾラクタム化合物
JP2002501516A (ja)	2002-01-15	スピロアザシクロ誘導体および治療薬としての該誘導体の使用
US20190142852A1 (en)	2019-05-16	Heterocyclic compounds for treating or preventing disorers caused by reduced neurotransmission of serotonin, norephnephrine or dopamine
US7119207B2 (en)	2006-10-10	Benzoamide piperidine containing compounds and related compounds
JP6033085B2 (ja)	2016-11-30	三環式誘導体ならびにそれらの医薬用途および組成物
JP3369123B2 (ja)	2003-01-20	ジ−又はトリアザ−スピロ〔４，５〕デカン誘導体
CN105793266B (zh)	2019-02-12	螺-噁唑酮
US20090281135A1 (en)	2009-11-12	3-azabicyclo [4. 1. 0] heptane derivatives for the treatment of depression
US20100029740A1 (en)	2010-02-04	Azabicyclic compounds as serotonin, dopamine and norepinephrine re-uptake inhibitors
JP5524183B2 (ja)	2014-06-18	Ｎｋ１タキキニン受容体アンタゴニストとしてのスピロ（ピペリジン−４，２’−ピロリジン）−１−（３，５−トリフルオロメチルフェニル）メチルカルボキサミド
JP6415982B2 (ja)	2018-10-31	複素環化合物
WO2009027293A1 (fr)	2009-03-05	Composés
WO2009056520A1 (fr)	2009-05-07	Dérivés d'azabicyclo[3.2.1]octane
JP2002536436A (ja)	2002-10-29	スピロ環ケトン類およびそれのタキキニン拮抗薬としての使用
JP2010536919A (ja)	2010-12-02	ノルエピネフリン、セロトニンまたはドーパミン再取り込み阻害剤として有用な３−アザビシクロ（４．１．０）ヘプタン誘導体
WO2010130672A1 (fr)	2010-11-18	Dérivés de l'azabicyclo [4.1.0] heptane et leur utilisation en tant qu'inhibiteurs de recapture de monoamines
JP2010536918A (ja)	2010-12-02	モノアミン再取り込み阻害剤として用いるための置換アザビシクロ［４．１．０］ヘプタン化合物